Published • loading... • Updated
FDA Approves Lilly's Mounjaro (Tirzepatide) to Reduce Cardiovascular Risk in Adults with Type 2 Diabetes
The approval is based on a trial of 13,299 patients that found Mounjaro cut major cardiovascular events by 8% versus Trulicity, Lilly said.
4 Articles
4 Articles
US FDA approves Lilly’s Mounjaro to reduce cardiovascular risk
Aug 28 (Reuters) - Eli Lilly said on Friday the U.S. FDA has approved its diabetes drug Mounjaro to lower the risk of major adverse cardiovascular events in adults with type 2 diabetes who are at high risk for these events. (Reportin...
Coverage Details
Total News Sources4
Leaning Left0Leaning Right1Center2Last UpdatedBias Distribution67% Center
Bias Distribution
- 67% of the sources are Center
67% Center
C 67%
R 33%
Factuality
To view factuality data please Upgrade to Premium
